دورية أكاديمية
أعرض في EDS

Antimicrobial Therapy Duration for Bloodstream Infections Caused by Pseudomonas aeruginosa or Acinetobacter baumannii-calcoaceticus complex : A Retrospective Cohort Study.

التفاصيل البيبلوغرافية
العنوان: Antimicrobial Therapy Duration for Bloodstream Infections Caused by Pseudomonas aeruginosa or Acinetobacter baumannii-calcoaceticus complex : A Retrospective Cohort Study.
المؤلفون: Rodrigues RD; Medical Sciences Post Graduation Program, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, Brazil., Garcia RCL; Medical Sciences Post Graduation Program, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, Brazil., Bittencourt GA; Medical School, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre 90619-900, Brazil., Waichel VB; Medical School, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre 90619-900, Brazil., Garcia ECL; Medical School, Pontifícia Universidade Católica do Paraná, Curitiba 80215-901, Brazil., Rigatto MH; Medical Sciences Post Graduation Program, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, Brazil.; Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, Brazil.; Infectious Disease Service, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, Brazil.
المصدر: Antibiotics (Basel, Switzerland) [Antibiotics (Basel)] 2023 Mar 08; Vol. 12 (3). Date of Electronic Publication: 2023 Mar 08.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101637404 Publication Model: Electronic Cited Medium: Print ISSN: 2079-6382 (Print) Linking ISSN: 20796382 NLM ISO Abbreviation: Antibiotics (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, 2012-
مستخلص: Background: Ideal therapy duration for Pseudomonas aeruginosa or Acinetobacter baumannii-calcoaceticus complex (ABC) bloodstream infections (BSI) is not defined, especially in the context of carbapenem resistance. In this study, we compared short- (≤7 days) and long-term (>7 days) antimicrobial therapy duration for these infections.
Methods: We performed a retrospective cohort study in two tertiary-care hospitals in Porto Alegre, Brazil, from 2013 to 2019. Eligible patients aged ≥18 years were included and excluded for the following criteria: polymicrobial infections, treatment with non-susceptible antibiotics, complicated infections, or early mortality (<8 days of active antimicrobial therapy). The 30-day mortality risk was evaluated using a Cox regression model.
Results: We included 237 BSI episodes, 51.5% caused by ABC and 48.5% by Pseudomonas aeruginosa . Short-term therapy was not associated with 30-day mortality, adjusted hazard ratio 1.01, 95% confidence interval 0.47-2.20, p = 0.98, when adjusted for Pitt score ( p = 0.02), Charlson Comorbidity Index score ( p < 0.01), and carbapenem resistance ( p < 0.01). Among patients who survived, short-term therapy was associated with shorter hospital stay ( p < 0.01). Results were maintained in the subgroups of BSI caused by carbapenem-resistant bacteria ( p = 0.76), ABC ( p = 0.61), and Pseudomonas aeruginosa ( p = 0.39).
Conclusions: Long-term therapies for non-complicated Pseudomonas aeruginosa and ABC BSI were not superior to short-term therapy for 30-day mortality.
References: Infect Dis Ther. 2022 Aug;11(4):1505-1519. (PMID: 35612693)
J Chronic Dis. 1987;40(5):373-83. (PMID: 3558716)
Clin Microbiol Infect. 2022 Apr;28(4):550-557. (PMID: 34508886)
Antibiotics (Basel). 2021 Apr 22;10(5):. (PMID: 33922151)
Expert Rev Anti Infect Ther. 2010 Jan;8(1):71-93. (PMID: 20014903)
Clin Microbiol Rev. 2021 Mar 10;34(2):. (PMID: 33692149)
J Antimicrob Chemother. 2021 Dec 24;77(1):223-228. (PMID: 34590681)
Clin Infect Dis. 2019 Nov 13;69(11):2011-2014. (PMID: 30882137)
Clin Microbiol Infect. 2023 Feb;29(2):165-170. (PMID: 36108947)
Clin Infect Dis. 2020 Dec 23;71(Suppl 4):S386-S393. (PMID: 33367574)
Curr Opin Infect Dis. 2021 Dec 1;34(6):681-685. (PMID: 34261908)
BMC Infect Dis. 2022 Apr 5;22(1):336. (PMID: 35382769)
Antimicrob Agents Chemother. 2019 Jun 24;63(7):. (PMID: 31010862)
BMC Infect Dis. 2021 Jul 2;21(1):636. (PMID: 34215207)
Clin Microbiol Infect. 2020 Feb;26(2):158-167. (PMID: 31733377)
Sci Rep. 2022 May 20;12(1):8527. (PMID: 35595789)
Open Forum Infect Dis. 2021 Oct 11;8(10):ofab434. (PMID: 34738022)
Shock. 2009 Feb;31(2):146-50. (PMID: 18636041)
Clin Infect Dis. 2009 Jul 1;49(1):1-45. (PMID: 19489710)
J Med Microbiol. 2023 Feb;72(2):. (PMID: 36753436)
Clin Infect Dis. 2019 Sep 13;69(7):1091-1098. (PMID: 30535100)
Clin Infect Dis. 2021 Apr 8;72(7):1109-1116. (PMID: 33830222)
معلومات مُعتمدة: 2019-0740 Research Incentive Fund of the Hospital de Clínicas de Porto Alegre.; finance code 001 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brasil (CAPES)
فهرسة مساهمة: Keywords: Acinetobacter baumannii-calcoaceticus complex; Pseudomonas aeruginosa; bloodstream infections; treatment duration
تواريخ الأحداث: Date Created: 20230329 Latest Revision: 20230331
رمز التحديث: 20230331
مُعرف محوري في PubMed: PMC10044637
DOI: 10.3390/antibiotics12030538
PMID: 36978405
قاعدة البيانات: MEDLINE
الوصف
تدمد:2079-6382
DOI:10.3390/antibiotics12030538